DBV Technologies | DBVT - Gewinn Vor Steuern

Aktienkurs
19.79
Täglich Wechseln
-0.20 -1.00%
Monatlich
-7.52%
Jährlich
101.32%
Q2 Prognose
19.41




Gewinn Vor Steuern Veränderung Datum
Acadia Pharmaceuticals USD 3.98M 22.34M 2026-03
Alnylam Pharmaceuticals USD 221.65M 60.52M 2026-03
Amarin USD -852K 7.26M 2025-12
BioCryst Pharmaceuticals USD 248.02M 235.89M 2025-12
BioMarin Pharmaceutical USD 141.2M 168.36M 2026-03
DBV Technologies USD -33.16M 8.6M 2025-09
Esperion Therapeutics USD 63.67M 95M 2025-12
Galectin Therapeutics USD -12.37M 880K 2024-06
Halozyme Therapeutics USD 218.96M 14.02M 2025-09
Incyte USD 343.6M 46.34M 2026-03
Insmed USD -162.1M 164.84M 2026-03
Ionis Pharmaceuticals USD -93M 135M 2026-03
Neurocrine Biosciences USD 246.8M 7.4M 2026-03
PTC Therapeutics USD -2.46M 136.62M 2026-03
Sarepta Therapeutics USD 343.17M 750.85M 2026-03
Ultragenyx Pharmaceutical USD -184M 56M 2026-03
United Therapeutics USD 444M 6M 2025-12